www.interpharma.co.th IP_OCS/011/2020 8th June 2020 Subject: Notify the Resolutions of the Board of Directors Meeting, Change of Objectives of Funds Usage, Acquisition of Assets, The Issuance of Debentures and Fix the
Katipagdeetham Independent Director and Member of the Audit Committee 9. Assoc. Prof. Dr.Chiraphol Chiyachantana Director and Secretary 3. Approved of the change of the authorized signatories of the Company
guideline above. 10.5 Personnel: specify the total number of the Company’s staff and that of each core business. In case of material change in the number of staff or a substantial labor dispute during the
, while the remaining 30 percent is sold into the Commonwealth of Australia’s National Electricity Market. 1.5 Change of the Company’s Name and Seal On April 12, 2019, the 2019 Shareholders’ Annual General
audit firm; (2) Not required if another auditor affiliated with the same audit firm has submitted an application and the document to the SEC Office, provided that there is no material change to the
change attend the ate) from J under the e Extraordin for holding gnation of D date to reco dinary Gen of Thailand on Names o 1) ting of Nati the “Comp ows, signation o rectors to re Mr.Apivut T lace Mr. Po
Kaewthipharat or Mr. Pisit Wannavalee and affix the Company’s seal. The value of the transaction based on value of consideration basis is 3.11%, calculated based of financial statement as at December 31, 2017
the audit firm …………….…... Note: Signatures of the head and the authorized person of the audit firm are required, together with the audit firm’s seal (if any). Form 61 – 2
…………….…... Note: Signatures of the head and the authorized person of the audit firm are required, together with the audit firm’s seal (if any). Form 61 – 2